ACIP greenlights PaxVax's cholera vaccine

cholera

In a unanimous vote, the CDC’s Advisory Committee on Immunization Practices recommended PaxVax’s oral cholera vaccine for adults traveling to areas where cholera is prevalent. The vaccine, dubbed Vaxchora, is the only licensed cholera vaccine in the U.S. and the only single-dose cholera vaccine in the world.

The ACIP nod comes two weeks after the FDA approved the vaccine. It recommends the live attenuated vaccine for adults aged 18 to 64. Previously, the CDC recommended the avoidance of contaminated food and water to fend off cholera infection, but studies show that as many as 98% of travelers tend not to follow this advice.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

While PaxVax lined up American travelers as its initial target, CEO Nima Farzan has previously told FierceVaccines that he plans to bring the vaccine to endemic countries as well.

The FDA approval was based on a 10-day and 90-day challenge study in addition to safety and immunogenicity trials in healthy adults. The vaccine posted 90% efficacy at the 10-day mark and 79% efficacy at the three-month mark. Its efficacy has not yet been proven in people from regions where cholera is endemic.

PaxVax expects Vaxchora to hit the market in September. PaxVax will use its existing sales structure to commercialize the vaccine. The Redwood City, CA-based company currently markets one vaccine, the typhoid jab Vivotif, that it picked up from Crucell two years ago.

- here's the statement

Related Articles:
PaxVax's cholera vaccine wins FDA nod
FDA accepts PaxVax's BLA for cholera vaccine, grants it priority review
Cerberus Capital management invests $105M in PaxVax

Read more on

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.